BIOCYTOGEN PHARMA. H YC1 (I54) — Cash Flow-to-Debt Ratio
BIOCYTOGEN PHARMA. H YC1 (I54) has a Cash Flow-to-Debt Ratio of 0.24x as of December 2025, meaning its operating cash flow of €370.25 Million could theoretically repay 0% of its total liabilities (€1.54 Billion) in one year. See how financially flexible is BIOCYTOGEN PHARMA. H YC1 to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BIOCYTOGEN PHARMA. H YC1 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for BIOCYTOGEN PHARMA. H YC1 across 5 annual periods. For the full cash flow conversion analysis, see I54 operating cash flow.
Annual Cash Flow-to-Debt Ratio for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
Year-by-year debt coverage analysis for BIOCYTOGEN PHARMA. H YC1. Check BIOCYTOGEN PHARMA. H YC1 (I54) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.24x | €370.25 Million | €1.54 Billion | ▲ +78.9% |
| 2024 | 0.13x | €211.25 Million | €1.58 Billion | ▲ +390.0% |
| 2023 | -0.05x | €-76.65 Million | €1.66 Billion | ▲ +74.9% |
| 2022 | -0.18x | €-303.27 Million | €1.65 Billion | ▲ +47.2% |
| 2021 | -0.35x | €-365.78 Million | €1.05 Billion | — |